Translational oncology - 26/05/2020 Translation: driver of cancer medicine The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field. https://www.gesundheitsindustrie-bw.de/en/article/news/translation-driver-cancer-medicine
Article - 11/06/2019 New pathogens in beef and cow's milk contributing to the risk of cancer A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
New edition - 24/05/2019 Tumour metastasis Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.https://www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
Article - 16/04/2019 Tumour monitoring using liquid biopsy Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Press release - 10/12/2018 High distinction for stem cell researcher Andreas Trumpp This year's State Research Prize of Baden-Württemberg awarded for outstanding achievements in applied research goes to Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). Theresia Bauer, State Minister of Science, Research and the Arts, presented the award, which carries a monetary prize of €100.000, at a festive ceremony on December 10, 2018.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-distinction-for-stem-cell-researcher-andreas-trumpp
Article - 18/01/2018 Medications that target metastasing tumours Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/medications-that-target-metastasing-tumours
Article - 11/12/2017 KDM4 – an efficient target for the therapy of triple-negative breast cancer While breast cancer survival has clearly improved in recent years, women with triple-negative breast cancer have benefitted very little from progress in cancer medicine. Targeted therapies aimed at inhibiting epigenetic regulators might offer a potential new option for the treatment of breast cancer. Prof. Dr. Roland Schüle and Dr. Jochen Maurer have discovered an epigenetic enzyme called KDM4 and come up with a new cell model that significantly…https://www.gesundheitsindustrie-bw.de/en/article/news/kdm4-an-efficient-target-for-the-therapy-of-triple-negative-breast-cancer
Article - 22/02/2017 MammaScreen – blood test for early detection of breast cancer The MammaScreen team from the University of Heidelberg Women’s Hospital has developed a blood test for diagnosing breast cancer. This new test can detect breast cancer at a very early stage. It works on women of all ages with tumours of any type and size. https://www.gesundheitsindustrie-bw.de/en/article/news/mammascreen-blood-test-for-early-detection-of-breast-cancer
Press release - 14/12/2016 amcure Raises €6 Million in Series B Financing and Expands Advisory Board Eggenstein-Leopoldshafen – 14 December 2016: amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, today announced the closing of a Series B financing round amounting to a total of EUR 6 million.https://www.gesundheitsindustrie-bw.de/en/article/press-release/amcure-raises-6-million-in-series-b-financing-and-expands-advisory-board
Article - 13/12/2016 Smart sensor technology from Ulm can do more than just breath analysis Detecting disease-specific molecules in human breath is technically feasible, but time-consuming and rather costly. "µbreath" could soon change this. The breath gas analysis device has all the necessary requirements for commercial success in the healthcare sector: it is compact, accurate, highly sensitive and fast. The chemist who developed µbreath, Prof. Boris Mizaikoff from Ulm University, and his partners are hoping to start…https://www.gesundheitsindustrie-bw.de/en/article/news/smart-sensor-technology-from-ulm-can-do-more-than-just-breath-analysis
Article - 05/09/2016 Apogenix: immuno-oncological protein drugs for the treatment of malignant diseases Apogenix AG, a biopharmaceutical company from Heidelberg that specialises in immuno-oncology, develops protein drugs that target central signalling pathways involved in regulating the growth, migration and apoptosis of malfunctioning cells and thus offer novel treatment options for cancer and other malignant diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/apogenix-immunonkologische-proteinwirkstoffe-gegen-maligne-erkrankungen
Article - 28/09/2015 Breast cancer: a few millilitres of urine to diagnose the disease early It would be phenomenal news if it turned out that breast cancer could be detected by way of urine samples. Treating physicians would be able to use conspicuous test results to begin further examinations as quickly as possible along with therapy if necessary. Prof. Dr. Elmar Stickeler and his team from the Freiburg University Medical Centre have developed a method that identifies the composition of microRNAs in urine. They were able to predict…https://www.gesundheitsindustrie-bw.de/en/article/news/breast-cancer-a-few-millilitres-of-urine-to-diagnose-the-disease-early
Article - 26/05/2015 Does too much beef and cow’s milk cause cancer? The large number of breast and colon cancer cases might be due to viruses that are taken up with beef and dairy products. This is the provocative thesis of Nobel Laureate Harald zur Hausen who previously linked HPV with cervical cancer. In addition to epidemiological evidence, zur Hausen and his team have also provided experimental evidence to substantiate his thesis.https://www.gesundheitsindustrie-bw.de/en/article/news/does-too-much-beef-and-cows-milk-cause-cancer
Article - 25/08/2014 Frederik Wenz - radiologist sets milestone with new surgical technique for the treatment of bone metastases Can painful bone metastases be treated in a targeted and quick way? Can metastases that are potentially present in the liver and kidneys be adequately treated at the same time as bone metastases? These are the questions that Professor Dr. med. Frederik Wenz from the University Medical Center Mannheim asked himself before going on to develop an innovative surgical technique. After a long development period, this technique is now recognized as an…https://www.gesundheitsindustrie-bw.de/en/article/news/frederik-wenz-radiologist-sets-milestone-with-new-surgical-technique-for-the-treatment-of-bone-metas
Article - 31/03/2014 TherapySelect – Identifying Susceptibility to Cancer Therapy TherapySelect Dr. Frank Kischkel is an innovative biotechnology company based in Heidelberg, Germany, with a special focus on the development, validation and application of diagnostic tests for cancer patients. The company’s proprietary CTR-Test® uses patients’ cancer cells to determine the tumor’s susceptibility to treatment with cytostatic drugs. This knowledge helps identify ineffective drugs prior to treatment as well as reduce adverse drug…https://www.gesundheitsindustrie-bw.de/en/article/news/therapyselect-identifying-susceptibility-to-cancer-therapy
Article - 04/07/2013 Experimental evidence of stem cells for metastasis For the first time, scientists from Heidelberg have characterised cancer cells that initiate metastasis in the blood of breast cancer patients using an in-vivo xenograft mouse model. These cells have the properties of cancer stem cells and are characterised by three surface molecules that can be used as biomarkers for disease progression. https://www.gesundheitsindustrie-bw.de/en/article/news/experimental-evidence-of-stem-cells-for-metastasis
Article - 21/05/2013 Green gold: bioactive plant foods Nowadays everything must be good for something must have a direct noticeable or tangible effect. The ever topical issue of nutrition is no exception. All this makes functional food a promising and inexhaustible market. Teams of scientists around the world are focussing on how unhealthy food can be made healthy. Bioactive plant foods are expected to close a gap that should not have existed in the first place. https://www.gesundheitsindustrie-bw.de/en/article/news/green-gold-bioactive-plant-foods
Article - 25/03/2013 Epigenetics for personalised cancer care for women Every year in the EU, 45,300 women are diagnosed with ovarian cancer and 330,000 with breast cancer. Ovarian cancer has a mortality rate of around 64% and breast cancer around 27%*. The EU-funded research project EpiFemCare aims at improving cancer detection and subsequent patient care. The research project aims to develop blood tests based on epigenetic DNA modifications, i.e. the methylation of the base cytosine, for the identification of…https://www.gesundheitsindustrie-bw.de/en/article/news/epigenetics-for-personalised-cancer-care-for-women
Article - 15/10/2012 Carmen Ruiz de Almodóvar and the link between the nervous and vascular systems Dr. Carmen Ruiz de Almodóvar from the Heidelberg University Biochemistry Centre has been awarded an ERC Starting Grant to study the molecular similarities between the nervous and vascular systems. The researcher showed that angiogenic factors such as VEGF also control the growth of neuronal cells and may be responsible for disorders in the development of nervous systems.https://www.gesundheitsindustrie-bw.de/en/article/news/carmen-ruiz-de-almod-var-and-the-link-between-the-nervous-and-vascular-systems
Press release - 24/08/2012 Cancer Survival in Germany after the fall of the Iron Curtain Two decades after the fall of the Wall, cancer survival rates in East and West Germany have become almost equal. This is reported in a recent study by a team of epidemiologists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and eleven German cancer registries. https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-survival-in-germany-after-the-fall-of-the-iron-curtain
Article - 16/04/2012 DNA recombination for targeted plant breeding Did evolution invent games of chance? During the development of sperm and egg cells, maternal and paternal genes are mixed at random, thus giving rise to new combinations of traits. What are the molecular mechanisms of this process known as DNA recombination? How can it be used to breed plants with higher yields? Prof. Dr. Holger Puchta and his team at the Karlsruhe Institute of Technology (KIT) are investigating the processes associated with the…https://www.gesundheitsindustrie-bw.de/en/article/news/dna-recombination-for-targeted-plant-breeding
Press release - 20/12/2011 No brakes on breast cancer cells Scientists of the German Cancer Research Center (DKFZ) have discovered a tiny RNA molecule, called miR-520, which at once blocks two important pathways in the development of cancer in cells. In estrogen receptor-negative breast cancer, the production of this microRNA is often reduced and this is correlated with malignant behavior of tumor cells. The DKFZ team has found out that tumors with low levels of miR-520 have a particularly strong tendency…https://www.gesundheitsindustrie-bw.de/en/article/press-release/no-brakes-on-breast-cancer-cells
Press release - 20/07/2011 Roche acquires mtm laboratories AG, expanding offering in cervical cancer Roche announced on July 19th that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. mtm is a global leader in developing in vitro diagnostics with a focus on early detection and diagnosis of cervical cancer, the largest early detection market in oncology. mtm will become part of Roche’s Tissue Diagnostics (Ventana Medical Systems, Inc.) business…https://www.gesundheitsindustrie-bw.de/en/article/press-release/roche-acquires-mtm-laboratories-ag-expanding-offering-in-cervical-cancer
Press release - 26/05/2011 High Scientific Level at the Second International Workshop about Drug-Drug Interactions The organisation team of the Second International DDI drug-drug interactions Workshop has expressed great satisfaction with the course of the scientific meeting. Thus the DDI Workshop at Marbach Castle is on its way to become an established platform for the annual exchange between experts scientists members of the industry and regulatory bodies regarding DDI affairs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-scientific-level-at-the-second-international-workshop-about-drug-drug-interactions